Publications library

Publications

Therapeutic Areas

Modeling & Meta-Analyses

Newest to Oldest

An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1

Authors: L A Evitt, S Nanji, R A Grove, C Okoli, J van Wyk, S Snedecor

Cost-effectiveness of Nivolumab plus Ipilimumab for the first-line treatment of intermediate/poor-risk advanced and/or metastatic renal cell carcinoma in Switzerland

Authors: E Çakar, C Oniangue-Ndza, R P Schneider, S L Klijn, U M Vogl, C Rothermundt, J R May

A probabilistic cost-effectiveness analysis of Venetoclax and Obinutuzumab as a first-line therapy in chronic lymphocytic leukemia in Canada

Authors: A Chatterjee, G van de Wetering, R Goeree, C Owen, A M Desbois, S Barakat, B S Manzoor, K Sail

Cost and clinical benefits associated with Oncotype DX® test in patients with early-stage HR+/HER2- node-negative breast cancer in the Netherlands

Authors: F E de Jongh, R Efe, K H Herrmann, J A Spoorendonk

48-Week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-Infected patients: A systematic review and network meta-analysis

Authors: D A Patel, S J Snedecor, W Yu Tang, L Sudharshan, J W Lim, R Cuffe, S Pulgar, K A Gilchrist, R Refoios Camejo, J Stephens, G Nichols

The clinical impact of multiple prevention strategies for respiratory syncytial virus infections in infants and high-risk toddlers in the United States

Authors: V Ektare, J Lang, Y Choi, L Finelli

Epidemiological and clinical characteristics of persons with transthyretin hereditary amyloid polyneuropathy: a global synthesis of 532 cases

Authors: M Waddington Cruz, H Schmidt, M F Botteman, J A Carter, A S Chopra, M Stewart, M Hopps, S Fallet, L Amass

Cost-effectiveness of perampanel for the treatment of primary generalized tonic-clonic seizures (PGTCS) in epilepsy: a Spanish perspective

Authors: G Tremblay, D Howard, W Tsong, V Patel, J De Rosendo

Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands

Authors: M A Piena, M Heisen, L W Wormhoudt, J van Wingerden, S T F M Frequin, B M J Uitdehaag

Multiple treatment comparison in narcolepsy: a network meta-analysis-methodological concerns

Authors: S J Snedecor, G Mayer, M J Thorpy, Y Dauvilliers

View older